Loading...
XSHG
600267
Market cap1.90bUSD
Jul 30, Last price  
11.73CNY
1D
-1.84%
1Q
32.39%
Jan 2017
-10.80%
IPO
173.28%
Name

Zhejiang Hisun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
22.79
P/S
1.40
EPS
0.51
Div Yield, %
—
Shrs. gr., 5y
3.67%
Rev. gr., 5y
-2.44%
Revenues
9.79b
-5.65%
1,905,870,4132,261,985,6062,838,770,7413,181,978,2634,003,470,4374,544,508,9595,161,394,2145,801,766,0628,604,311,58310,096,747,8628,767,428,1409,733,423,46010,571,526,72310,187,440,96511,071,784,24211,354,395,74312,136,465,76512,036,690,08110,373,071,9569,786,848,052
Net income
601m
115,876,71280,338,876139,672,066195,320,954272,250,101365,761,620504,081,307301,289,979301,857,409307,896,70613,566,704013,566,2260323,265,742723,167,293486,888,358488,860,0510601,182,827
CFO
2.11b
+39.39%
113,527,315108,028,871437,720,980221,276,654472,846,967509,179,184525,312,010375,746,180527,249,352571,038,090736,168,523775,899,3371,240,708,2471,446,308,104698,388,3711,589,608,7561,736,524,2432,065,736,6081,516,960,5452,114,532,552
Dividend
May 19, 20230.17 CNY/sh

Profile

Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taizhou, China.
URL
http://www.hisunpharm.com/
IPO date
Jul 25, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,786,848
-5.65%
10,373,072
-13.82%
12,036,690
-0.82%
Cost of revenue
7,224,566
9,114,122
10,099,395
Unusual Expense (Income)
NOPBT
2,562,282
1,258,950
1,937,295
NOPBT Margin
26.18%
12.14%
16.09%
Operating Taxes
126,760
14,148
192,003
Tax Rate
4.95%
1.12%
9.91%
NOPAT
2,435,522
1,244,802
1,745,292
Net income
601,183
 
488,860
0.40%
Dividends
(199,183)
(166,258)
Dividend yield
1.83%
1.31%
Proceeds from repurchase of equity
(109,231)
BB yield
1.00%
Debt
Debt current
2,160,812
2,167,747
3,038,943
Long-term debt
1,124,047
2,426,728
3,121,877
Deferred revenue
164,582
185,963
207,152
Other long-term liabilities
2
74,080
Net debt
1,787,211
1,593,261
3,173,247
Cash flow
Cash from operating activities
2,114,533
1,516,961
2,065,737
CAPEX
(240,039)
Cash from investing activities
(338,706)
Cash from financing activities
(1,004,207)
FCF
3,261,413
2,512,881
2,594,844
Balance
Cash
1,497,648
1,586,920
1,398,783
Long term investments
2
1,414,294
1,588,790
Excess cash
1,008,305
2,482,560
2,385,739
Stockholders' equity
3,974,609
3,437,532
4,500,645
Invested Capital
10,961,839
10,692,224
12,057,959
ROIC
22.49%
10.94%
13.86%
ROCE
21.36%
9.54%
13.40%
EV
Common stock shares outstanding
1,156,121
1,164,641
1,152,571
Price
8.30
-11.32%
9.36
-15.06%
11.02
-21.23%
Market cap
9,595,803
-11.97%
10,901,043
-14.17%
12,701,330
-20.01%
EV
11,620,674
12,741,743
16,125,679
EBITDA
3,649,701
2,303,517
2,977,223
EV/EBITDA
3.18
5.53
5.42
Interest
155,900
215,402
283,124
Interest/NOPBT
6.08%
17.11%
14.61%